Clinical decision support system for early detection of cognitive decline using electronic health records and deep learning
Ended Project Grant Awarded Last action
- Award ID
- R44AG081006
- Recipient
-
Melax Technologies Inc. UEI ME3MA61LJD79
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,485,780
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date
- Place of performance
- Texas, USA
Award details come from USAspending.gov.
Description
- Abstract
- The prevalence of alzheimer's disease (ad) and related dementia (ad/ADRD) is expected to nearly triple to a staggering 13 million affected americans and the total costs of care are projected to increase five-fold to 1.1 trillion dollars by the year 2050. Early detection of precursor stages of ad/ADRD becomes extremely important, as IT can introduce treatment or intervention earlier for potential ad/ADRD patients, given existing treatments only have modest benefit at best. Early cognitive decline of patients is often under diagnosed by primary care physicians (PCPS). A clinical decision support (CDS) tool that can automatically detect cognitive decline signals from longitudinal electronic health records (EHRS) and facilitate PCPS to make timely diagnoses would be highly desirable, as IT would result in early intervention for potential ad/ADRD patients. In our phase I equivalent work at harvard medical school, we have developed a deep learning model for earlier detection of cognitive decline using clinical notes in mass general brigham's EHRS. Here we propose a direct-to-phase II study, which further develops novel deep learning algorithms for the early detection of cognitive decline, implement them into a clinical decision support tool, and validate the tool in a primary care setting. Specifically, in aim 1, we will develop novel ontology, NLP, and classification approaches to identify patients with early cognitive decline using records from EHR and extract related evidence from clinical notes. In aim 2, we will work with frontline physicians to design, develop and evaluate a user-centered clinical decision support tool to identify and manage patients with cognitive decline. The system, which we intend to align with evidence-based frameworks such as the CMS collaborative care model, will identify patients at risk (with supporting evidence) and prompt personalized recommendations for timely care. Once the system is developed and fully tested, we will implement the developed CDS tool in a simulated EHR environment at mass general brigham healthcare system, using real patient data, and formally evaluate its utility and usability by recruiting primary care clinicians. This project will deliver not only effective models for early detection of cognitive decline, but also a practical and validated CDS tool that can improve diagnosis of precursor stages of ad/ADRD, thus facilitating early intervention for potential ad/ADRD patients. If successful, IT will be the first study that engages primary care physicians and real patient data to validate the utility of such a cognitive decline detection tool.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,121,445 | |
| Amendment | $1,121,445 | |
| Amendment | $1,121,445 | |
| Original award | $1,121,445 |
Quick answers
Who received award R44AG081006?
R44AG081006 was awarded to Melax Technologies Inc. by National Institute on Aging (National Institutes of Health) on February 1, 2023.
How much is award R44AG081006 worth?
$4,485,780 has been obligated on R44AG081006.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award